Sanofi (SNY) Operating Expenses (2009 - 2026)

Sanofi has disclosed Operating Expenses across 18 years of filings, most recently posting -$6.0 billion for Q2 2026.

• In Q2 2026, Operating Expenses fell 16.87% year-over-year to -$6.0 billion; the TTM figure through Jun 2026 stood at -$47.8 billion (down 42.96% YoY), while the FY2025 annual figure was $18.9 billion, up 197.22% from the prior year.
• Operating Expenses came in at -$6.0 billion for Q2 2026 at Sanofi, down from -$5.1 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$4.5 billion in Q1 2025 to a low of -$21.6 billion in Q4 2025.
• Average Operating Expenses over 5 years is -$8.6 billion, with a median of -$5.0 billion recorded in 2025.
• Year-over-year, Operating Expenses climbed 10.27% in 2022 and sank 229.95% in 2025.
• Over 5 years, Operating Expenses stood at -$16.7 billion in 2022, then retreated by 5.87% to -$17.7 billion in 2023, then slipped by 8.38% to -$19.2 billion in 2024, then declined by 12.27% to -$21.6 billion in 2025, then jumped by 72.28% to -$6.0 billion in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were -$6.0 billion in Q2 2026, -$5.1 billion in Q1 2026, and -$21.6 billion in Q4 2025.